symadex

Description: Symadex (formerly XLS-002, C-1311, and imidazoacridone) is a novel anticancer agent of the imidazoacridinone class which has been recommended for Phase II clinical trials a few years ago, it has shown activity in experimental tumour models both in vitro and in nude mice. C-1311 at the EC(99) dose delayed progression of cells through the S phase which was followed by G2 arrest. C-1311 does not induce rapid apoptosis in HT-29 cells, instead drug exposure leads to prolonged G2 arrest followed by G2 to M transit and cell death during mitosis in the process of mitotic catastrophe.

References: J Pharmacol Exp Ther. 2013 Sep; 346(3):393-405.

Related CAS #: 138154-39-9 (free base); 138154-55-9 (HCl)